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Purpose: Few data exist on high cardiovascular risk (HCVR) prevalence
within a primary prevention population. The goals of the present study were:
1) to assess HCVR distribution according to SCORE, in France, for high-risk
primary care patients not treated for dyslipidemia; 2) to compare risk assess-
ment by physician and risk SCORE estimate; 3) to define the excess of risk
(ER) due to other risk factor than age.
Methods: This observational study was conducted over a week within a
representative sample of French general practitioners (GP). All consulting pri-
mary care men/women aged ≥50/60 y, with at least one other risk factor (RF)
(smoking, high blood pressure (HBP), type 2 diabetes, HDL-c<0.40 g/L), not
treated for dyslipidemia were included in the study. GP filled-in an on line
questionnaire that enabled SCORE risk calculation in real time. ER was cal-
culated from a “theoretical” SCORE, namely patient with no RF: total choles-
terol=6 mmol/L, Systolic BP=120 mmHg, no smoking.
Results: GPs (n=1147) included 9049 patients with the following charac-
teristics: mean age: 68y; male: 57%; LDLc>1.3 g/L: 57%; smoking: 21%;
HBP: 44%; type 2 diabetes: 21% HDL-c<0.4 g/L: 16%. According to SCORE,
50% of the patients were at HCVR. CVR was correctly assessed for 45.9% of
the patients and under estimated for 62.8% HCVR patients. There was little
correlation between GPs risk assessment and SCORE results: Kappa=0.078
[IC95%=0.062-0.094]; weighted Kappa=0.097 [0.082-0.112]. Mean ER
increased with age, from 1.1/0.9% to 4.5/3.6% for male (50y to >75y))/female
(60y to >75y). At the end of the study, 85% of the GP declared that SCORE
was useful in HCVR identification and 87% declared that they will use it in
the future.
Conclusion: In France, 50% of the patients consulting in primary care with
at least 1 RF on top of age and no lipid-lowering treatment have a high
SCORE. GPs tend to underestimate their patient’s risk as compared to objec-
tive SCORE risk assessment. Excess risk increases with age.
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Aim: To determine the prevalence of hypertension among schoolchildren
in Brazzaville.
Patients and methods: a prevalence survey was conducted from March to
May 2011 in five urban schools in Brazzaville. The survey was random at
three levels. The variables studied were clinical and epidemiological.
Results: 603 children divided into 325 girls (54%) and 278 boys (46%)
were examined. The average age was 11.8±3.6 years (range 5-18 years). There
was 315 children (52.2%) from primary schools and 319 (53%) from private
schools. The social level was average or higher in 360 cases (60%). The mean
SBP was 112.8±13 mm Hg (range 79-150) and the mean DBP was
73.6±8.8 mm Hg (range 48-104). Obesity was noted in 25 cases (4.1%), and
overweight in 47 cases (7.8%). Hypertension was found in 61 cases (10.1%)
during the first screening, and in 20 cases (3.3%) during the second screening.
Factors correlated with hypertension were obesity (OR 6.6, 95% CI 2-21) and
overweight (OR 5.6, 95% CI 2-15).
Conclusion: the fight against obesity and overweight in our children by
promoting food and physical activity which will reduce the incidence of
hypertension.
Keywords: hypertension, children, school, Brazzaville
256
Ramadan fasting and high sensitive CRP in patients with stable coro-
nary artery disease: a pilot study
Faouzi Addad (1), Majdi Amami (1), Nadia Hammami (1), Sami
Gargouri (1), Sonia Marrakchi (2), Houssine Chammem (1), Wacef
Ayedi (1), Afef Ben Halima (2), Ikram Kammoun (2), Sadek Yahlaoui (3),
Salem Kachboura (2)
(1) EPS Abderrahmen Mami, service de cardiologie, Ariana, Tunisie –
(2) CHU A. Mami, service de cardiologie, Ariana, Tunisie – (3) EPS
Abderrahmen Mami, department of medical biology, Ariana, Tunisie
Introduction: Ramadan fasting is one of the five pillars observed by
Muslim adults worldwide. Data on incidence of acute coronary syndrome
during fasting Ramadan are scarce and conflicting. Inflammation plays a
major role in atherothrombosis, and measurement of cardiac biomarkers such
as High sensitive C-reactive protein (hs-CRP) may provide a strong indepen-
dent predictor of future cardiac events.
Aim of this study: was to evaluate the effect of fasting during Ramadan
on hs-CRP in patients with stable coronary artery disease (CAD).
Patients and Methods: it was a prospective pilot study among 27 patients
with stable CAD (within the last 6 months) who were observed before and at
the end of Ramadan fasting. Patients were recruited from outpatients depart-
ment. Twenty one were males and 6 were females with a mean age of
59±8.2 years (52-75 y). Fifteen patients had hypertension, 10 were smokers
and 7 were diabetics. Blood was analyzed at the first visit was a week before
the onset of Ramadan and the second visit at the third week of Ramadan. The
assay of hs-CRP was done with the collected sera by Demeditec Diagnostics
Systems Laboratories (Germany).
Results: Six patients were excluded for the second visit due to various rea-
sons (break voluntary of fasting in two cases, 4 patients with concurrent
inflammatory disorders e.g. rheumatoïd disease in 2 cases and intercurrent
infections in two others). A total of 21 subjects were screened during this
period. There was a significant reduction in hs-CRP during Ramadan com-
pared before this period: 6.6±8.7 vs 3.8±5.5 (p <0.0001). The mean variation
of hs-CRP during this holy period was – 39.3±– 20.9 (0% à – 68.3%). The hs-
CRP level was less than 3 mg/l in 10 patients (47.6%) before compared to
13 pts (62%) during Ramadan. The reduction of hs-CRP was independent of
the risk factors or the dosage of statins.
Conclusion: The practice of fasting during the month of Ramadan by the
people with stable CAD might be cardio-protective as it resulted in the low-
ering of hs-CRP.
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Purpose: Few data exists on high cardiovascular risk (HCVR) prevalence
within a primary prevention population. The goal of the study was to assess
HCVR distribution, according to SCORE, in France for high-risk primary care
patients not treated with lipid-lowering drug.
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Methods: This observational study was conducted over a week on a repre-
sentative sample of French general practitioners (GP). All consulting primary
care men/women ≥50/60 y, with at least one other CVR factor (smoking, high
blood pressure (HBP), type 2 diabetes, HDL-c<0.40 g/L), not treated for dys-
lipidemia were included in the study. GP filled-in an on line questionnaire that
enabled SCORE calculation.
Results: GPs (n=1147) included 9049 patients with the following charac-
teristics: mean age: 68 y; male: 57%; LDLc>1.3 g/L: 57%; smoking: 21%;
HBP: 44%; type 2 diabetes: 21% HDL-c<0.4 g/L: 16%. 
According to SCORE, HCVR prevalence reached 50% in total population
(male: 49%, female: 51%). 50% of HCVR men/women were older than
>72.4/78.8 y. HCVR patients were older by 7.7/6.8 y for male/female (p <0.01)
than non-HCVR patients. Other significantly more frequent characteristics in
high CVR population are: HDL≥0.6 g/L (38%), untreated or uncontrolled
HBP (53%) and left ventricular hypertrophy (8%). Obesity is less frequent
(15%) in high CVR population. Highest HCVR prevalence was observed in
the Mediterranean population (54%), and lowest (47%) in the Northeast pop-
ulation (p <0.01). Adjustment by age and gender reduces regional disparities
between regions (52% vs 48%).
Conclusions: Half consulting primary care patients aged ≥50/60 y for men/
women with at least 1 risk factor on top of age and no lipid-lowering treat-
ment are at HCVR according to SCORE risk equation. Assessing cardiovas-
cular risk with risk equations appears particularly useful in this group of
patients. Besides age, which has the strongest impact on risk estimation, other
RF may be screened to improve HCVR management.
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Purpose: Prior studies have recognised non-O blood type as a risk factor
for venous thromboembolism (VTE). Though, ABO blood type contribution to
VTE recurrence risk is poorly studied. We sought to determine the impact of
blood type on VTE recurrences.
Methods: Our prospective cohort included 120 subsequent patients pre-
senting a first episode of pulmonary embolism (PE). In all cases, PE were
diagnosed with a CT scan. All participants were followed for at least
12 months after anticoagulation therapy discontinuation.
Results: Over a mean follow-up period of 30 months, the rate of recur-
rence was 8.9% per patient and per year. PE was unprovoked in 63 patients
(52.5%). Mean duration of oral anticoagulation was 6 months. Compared to O
blood type, the unadjusted hazard ratio (HR) of VTE recurrence for non-O
blood type was 1.97 (95%CI, 0.91-4.26, p=0.07). B blood type exposed to a
higher risk of VTE recurrence than O blood type with a HR of 2.6 (95%CI,
1.12-6.06, p=0.03). A and AB blood types were not associated with an
increased risk of VTE recurrence when compared to O blood type.
Conclusion: Non O blood type are involved not only in the occurrence of
a first episode of VTE but tend to contribute to VTE recurrence. Patients with
B blood type develop more VTE recurrence than others. The ABO blood type
could be one of the characteristics to be studied for the determination of the
length of anticoagulant treatment after a first episode of VTE
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Purpose: Statins have demonstrated their efficacy in many situations to
prevent cardiovascular risk. In this work we investigated the link between
chronic use of statins, type of subsequent acute coronary syndrome (ACS),
namely ST-elevation myocardial infarction (STEMI) or unstable angina/non
ST-elevation myocardial infarction (UA/NSTEMI), early complications and
their impact on one-year mortality in real life conditions.
Methods: Our study was based on 2006 data from the French MONICA
population-based registry which collects all cases of ACS occurring in people
aged 35-74 in 3 French areas. The sample consisted of 1951 hospitalized inci-
dent ACS (72 were excluded because of missing data). Relationship between
chronic use of statins and type of ACS or early complications (resuscitated
cardiac arrests and shocks) were analyzed through logistic regression. Impact
on one-year mortality was evaluated through Cox models. Analyses were
adjusted for patients’ characteristics (living area, age, gender and previous car-
diovascular treatments).
Results: Before index event, the rate of statins treated patients was
18%. The percentage of UA/NSTEMI among all hospitalized ACS was
45%; 54.5% in patients with previous statins treatment and 42.9% in those
without (p<0.0001). The adjusted odds ratio (OR) for UA/NSTEMI was
1.29 (p=0.049) for subjects with versus those without statins. There was a
significant association between statins and early complications (adjusted
OR 0.58; p=0.030). Statins treatment prior to event was associated with a
significant decrease in one-year mortality with an adjusted HR equal to
0.62 (p=0.017).
Conclusions: In our registry, people already treated with statins before an
incident ACS had a lower rate of one-year mortality. This may result from a
lower probability to develop STEMI, or early complications. However it
remains difficult to assess from these observational data what is related to the
treatment and what is related to potential confounding bias.
260
Cognitive performance, cerebral oxygenation, exercise capacity and
cardiac output in patients with coronary heart disease
Vincent Gremeaux (1), Joffrey Drigny (2), Mathieu Gayda (2), Louis
Bherer (3), Philippe Sosner (4), Martin Juneau (2), Anil Nigam (2)
(1) CHU Dijon, Pôle rééducation-réadaptation, Dijon, France – (2) Centre
ÉPIC, Institut de cardiologie de Montréal, Montréal, Canada – (3) Institut
universitaire gériatrique de Montréal et UQAM, Montréal, Canada –
(4) CHU de Poitiers, service de cardiologie – Université de Poitiers, EA
3813, Poitiers, France
Objectives: Recent data suggested that coronary heart disease (CHD) is
associated with non-amnesic mild cognitive impairment. Our purpose was to
assess cognitive performances at rest, VO2max, cardiac output (CO), and
cerebral hemodynamic changes during maximal exercise in patients with
stable CHD.
Methods: 22 stable fit CHD patients (70,9±9,3 years), 10 healthy age-
matched (68,6±8,6 years), 10 middle aged controls and 10 young controls
(< 40y) were included. We assessed cognitive performance with a standard
battery of paper and pencil tests, maximal exercise test on ergocycle with gas
exchange analysis with non-invasive CO measurement and Near-Infrared
Spectroscopy (NIRS) oxygenation indices at the brain level.
Results: There was no intergroup difference in VO2max or maximal CO
between cardiac and healthy age-matched individuals. Some cognitive tests,
especially for executive functioning, were significantly better for the healthy
matched group (Trail Making Test-B; Inhibition/Flexibility Stroop Task and
Backward Digit Span, p<0.05). For NIRS signals, we observed an increase in
deoxyhemoglobin (HHb) for maximal intensities and the classical inverted U-
shape curve for oxyhemoglobin (O2Hb) and hemoglobin difference
(Hbdiff=O2Hb-HHb) in each group. Considering fitness, intra-CHD group
